Delving into the Latest Updates on Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Colony-stimulating factors

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	2

Top 5 Drug Type	Count

Colony-stimulating factors	2

Top 5 Target	Count

EPO receptor(Erythropoietin receptor)	1
CSF-3R(Colony stimulating factor 3 receptor)	1

观察健康受试者接受单次皮下注射聚乙二醇化重组人粒细胞集落刺激因子注射液的安全性，耐受性，评估该药的安全剂量范围，考察本品在健康人的药代动力学和药效学特点，确定健康人体的最大耐受剂量，为本品后期临床研究提供依据。

[Translation]

To observe the safety and tolerability of a single subcutaneous injection of pegylated recombinant human granulocyte colony stimulating factor injection in healthy subjects, evaluate the safe dosage range of the drug, investigate the pharmacokinetic and pharmacodynamic characteristics of this product in healthy subjects, determine the maximum tolerated dose in healthy subjects, and provide a basis for the later clinical research of this product.

Start Date03 Dec 2020

Sponsor / Collaborator

Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

100 Clinical Results associated with Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

Login to view more data

100 Deals associated with Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human erythropoietin(Sinobioway Xinpeng) ( EPO receptor )	Anemia More	Approved
Recombinant human granulocyte colony-stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.) ( CSF-3R )	Neutropenia More	Approved
PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.) ( CSF-3R )	Neutropenia More	Suspended
TNF-related apoptosis-inducing ligand (Xinpeng Bio) ( TRAIL )	Neoplasms More	Pending
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.) ( DR4 x DR5 )	Neoplasms More	Pending